Our free daily oncology focused e-news service.
Subscribe» | Search Archives»
(Medscape Medical News) July 29, 2014 - This summer, results from the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial sparked a controversy that is gathering momentum.
read article (free registration required) »
(Bayer) July 30, 2014 – The oncology compound Stivarga® (regorafenib) from Bayer has been approved by the European Commission (EC) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.
read corporate press release »
(NPR Shots blog/Kaiser Health News) July 29, 2014 - It's a painful dilemma for seriously ill Medicare patients: To receive the extra support, counseling and care provided by the program's hospice benefit, they have to agree to stop receiving curative treatment for their disease.
read article »
News Story Commentary By Academic and Community Oncologists
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
Sunesis Pharmaceuticals, Inc. has 2 jobs posted.
Novocure has posted 4 jobs.